![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BCAN |
Gene summary for BCAN |
![]() |
Gene information | Species | Human | Gene symbol | BCAN | Gene ID | 63827 |
Gene name | brevican | |
Gene Alias | BEHAB | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q96GW7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63827 | BCAN | P2T-E | Human | Esophagus | ESCC | 7.52e-23 | 7.50e-01 | 0.1177 |
63827 | BCAN | P56T-E | Human | Esophagus | ESCC | 1.10e-03 | 7.37e-01 | 0.1613 |
63827 | BCAN | P76T-E | Human | Esophagus | ESCC | 1.96e-05 | 4.40e-01 | 0.1207 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00215436 | Esophagus | ESCC | pallium development | 94/8552 | 169/18723 | 5.79e-03 | 2.14e-02 | 94 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCAN | SNV | Missense_Mutation | c.2047N>A | p.Val683Ile | p.V683I | Q96GW7 | protein_coding | tolerated(0.57) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
BCAN | SNV | Missense_Mutation | novel | c.761A>C | p.Asp254Ala | p.D254A | Q96GW7 | protein_coding | deleterious(0.01) | benign(0.146) | TCGA-DF-A2L0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
BCAN | SNV | Missense_Mutation | novel | c.1306N>G | p.Thr436Ala | p.T436A | Q96GW7 | protein_coding | tolerated(0.5) | benign(0.01) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
BCAN | SNV | Missense_Mutation | novel | c.1593N>T | p.Arg531Ser | p.R531S | Q96GW7 | protein_coding | tolerated(0.55) | benign(0.026) | TCGA-EY-A1G7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BCAN | SNV | Missense_Mutation | rs574942413 | c.820C>T | p.Arg274Trp | p.R274W | Q96GW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.849) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BCAN | SNV | Missense_Mutation | novel | c.441C>A | p.Ser147Arg | p.S147R | Q96GW7 | protein_coding | tolerated(0.08) | possibly_damaging(0.654) | TCGA-EY-A1GQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
BCAN | SNV | Missense_Mutation | novel | c.1989N>T | p.Glu663Asp | p.E663D | Q96GW7 | protein_coding | tolerated(0.55) | benign(0.228) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BCAN | SNV | Missense_Mutation | novel | c.1850N>T | p.Arg617Ile | p.R617I | Q96GW7 | protein_coding | tolerated(0.05) | possibly_damaging(0.737) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
BCAN | SNV | Missense_Mutation | novel | c.770N>C | p.Gly257Ala | p.G257A | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BD-A2L6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
BCAN | SNV | Missense_Mutation | novel | c.598N>A | p.Tyr200Asn | p.Y200N | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-DD-AAC8-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |